CAJ | 학술논문

目的：探讨miRNA-144在骨髓增生异常综合征(MDS)患者外周血中的表达情况及其临床意义。方法收集MDS患者24例，健康对照12例，qRT-PCR检测外周血miRNA-144相对表达量，统计分析miRNA-144在MDS中的表达情况及与其预后相关性。结果 miRNA-144在MDS亚型难治性血细胞减少伴单系病态造血(RCUD)、难治性血细胞减少伴多系病态造血(RCMD)、难治性贫血伴环形铁粒幼细胞(RARS)、难治性贫血伴原始细胞增多-1(RAEB-1)及难治性贫血伴原始细胞增多-2(RAEB-2)中的相对表达量分别为3.81、3.64、4.56、6.49及8.73，均显著高于健康对照组，P＜0.01；miRNA-144在预后好和预后差组中的相对表达量分别为3.81和7.18，差异具有统计学意义，P<0.01。结论 miRNA-144在MDS中高表达，且可作为潜在的预后评估指标。
목적：탐토miRNA-144재골수증생이상종합정(MDS)환자외주혈중적표체정황급기림상의의。방법수집MDS환자24례，건강대조12례，qRT-PCR검측외주혈miRNA-144상대표체량，통계분석miRNA-144재MDS중적표체정황급여기예후상관성。결과 miRNA-144재MDS아형난치성혈세포감소반단계병태조혈(RCUD)、난치성혈세포감소반다계병태조혈(RCMD)、난치성빈혈반배형철립유세포(RARS)、난치성빈혈반원시세포증다-1(RAEB-1)급난치성빈혈반원시세포증다-2(RAEB-2)중적상대표체량분별위3.81、3.64、4.56、6.49급8.73，균현저고우건강대조조，P＜0.01；miRNA-144재예후호화예후차조중적상대표체량분별위3.81화7.18，차이구유통계학의의，P<0.01。결론 miRNA-144재MDS중고표체，차가작위잠재적예후평고지표。
Objective To investigate the expression and clinical significance of serum circulating miRNA-144 in the patients with myelodysplastic syndromes. Methods The miRNA-144 expression levels were detected by qRT-PCR method in 24 MDS pa-tients and 12 health controls. The relationship between miRNA-144 expression level and MDS prognosis was analyzed. Results The relative expression quantity of miRNA-144 in MDS subtype RCUD, RCMD, RARS, RAEB-1 and RAEB-2 was 3.81, 3.64, 4.56, 6.49 and 8.73 respectively, and significantly higher than that of healthy controls (P<0.01). In good survival group and poor survival group, the relative expression quantity of miRNA-144 was 3.81 and 7.18 respectively, and the difference was statistically significant (P<0.01). Conclusion miRNA-144 is highly expressed in MDS, and may be a new biomarker for prognosis evaluation of MDS.